WO2021145742A1 - Composition d'amélioration de la fonction athlétique, comprenant de la phlorotannine comme ingrédient actif - Google Patents

Composition d'amélioration de la fonction athlétique, comprenant de la phlorotannine comme ingrédient actif Download PDF

Info

Publication number
WO2021145742A1
WO2021145742A1 PCT/KR2021/000645 KR2021000645W WO2021145742A1 WO 2021145742 A1 WO2021145742 A1 WO 2021145742A1 KR 2021000645 W KR2021000645 W KR 2021000645W WO 2021145742 A1 WO2021145742 A1 WO 2021145742A1
Authority
WO
WIPO (PCT)
Prior art keywords
ecklonia
composition
formula
improving
phlorotannin
Prior art date
Application number
PCT/KR2021/000645
Other languages
English (en)
Korean (ko)
Inventor
이행우
신현철
오재근
Original Assignee
주식회사 만나스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200006556A external-priority patent/KR20210093408A/ko
Priority claimed from KR1020210005925A external-priority patent/KR102594284B1/ko
Application filed by 주식회사 만나스 filed Critical 주식회사 만나스
Publication of WO2021145742A1 publication Critical patent/WO2021145742A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • the present invention relates to a composition for improving motor function of humans, particularly those aged 60 years or older, and a product comprising the same, and to a composition comprising a specific combination of Ekcol-based compounds and having an effect of improving reduced motor function and a product comprising the same it's about
  • the human musculoskeletal system is a system that enables human movement. Anatomically, it consists of bones, muscles, cartilage, ligaments, etc., and exists as an integrated system throughout the human body through the vascular system, the nervous system and the immune system. do.
  • the health of the musculoskeletal system is an essential element of life that enables human beings to live independently.
  • body protection, dynamic function, and beauty can be made possible by controlling the magnitude and strength of the movement of the extremities and performing flexible and balanced movements.
  • the normal function of the musculoskeletal system is absolutely important for survival and human dignity, as well as for physical beauty, athletics and artistic dimensions.
  • musculoskeletal dysfunction due to trauma can be recovered by appropriate surgical and physical therapy procedures, except for cases that cause disability.
  • one or more elements constituting the musculoskeletal system enter into a chronic exacerbation process due to after-traumatic trauma, chronic stress, and aging, the functional range of the musculoskeletal system is reduced, and again the normal function of the musculoskeletal system is reduced, such as decreased muscle mass, decreased bone density, decreased peripheral blood flow, etc.
  • Motor function gradually deteriorates through positive feedback in such a way that structural elements necessary for functional implementation deteriorate, and eventually, various risks are exposed and the quality of life is greatly reduced.
  • the present inventors recognized the need for a more integrated approach in a method of improving motor function through recovery of musculoskeletal function, and studied a motor function improvement model linked to musculoskeletal function as shown in FIG. 1 .
  • essential physical elements that the musculoskeletal system must have for smooth movement functions of the human body, including the ability to walk upright, were analyzed into three categories: strength, flexibility, and sense of balance of musculoskeletal tissue. When any one of these three factors worsens, the function of the musculoskeletal system gradually deteriorates in a way that adversely affects the other factors, resulting in a rapid decline in motor function.
  • the present inventors intend to provide a composition and product that can be expected to improve the motor function of humans, especially those aged 60 years or older, by exerting an overall improvement effect on the musculoskeletal system by easily ingesting it with confidence.
  • the present invention provides a composition for enhancing or improving exercise function comprising a phlorotannin compound as an active ingredient.
  • the present invention provides a composition for enhancing or improving motor function by improving at least one of musculoskeletal tissue, flexibility, and sense of balance.
  • the present invention provides a composition for enhancing or improving athletic function by improving at least one of muscle mass and bone density.
  • the present invention provides a product for enhancing or improving exercise function comprising the composition.
  • compositions and products containing phlorotannin as an active ingredient of the present invention are safe and easy to use as a natural material, and improve the musculoskeletal tissue, flexibility and sense of balance, which are three aspects essential for the smooth functioning of the musculoskeletal system, by using a small amount. It has the effect of enhancing and improving motor function.
  • Compositions and products containing phlorotannin as an active ingredient of the present invention are particularly effective in improving muscle mass and/or bone density.
  • FIG. 1 shows a model for improving motor function linked to a musculoskeletal system function.
  • Figure 2 shows the organic relationship between the process of deterioration of motor function due to the weakening of the musculoskeletal system and related factors.
  • the present invention provides a composition for enhancing or improving exercise function comprising a phlorotannin compound as an active ingredient.
  • the present invention provides a composition capable of enhancing or improving motor function through restoration of musculoskeletal function.
  • the present invention provides a composition that enhances and improves motor function through improvement of three aspects essential for smooth functioning of the musculoskeletal system: musculoskeletal tissue, flexibility, and sense of balance.
  • stem cells Stemcells in the case of muscle; satellite cells in the case of bone
  • NFkB a redox-sensitive transcriptional factor in mesenchymal stem cells
  • oxidative stress in the musculoskeletal system increases, the regeneration rate is reduced compared to the decomposition rate of muscle and bone tissue, blood flow decreases, and dehydration of cells occurs, thereby entering a vicious cycle of deterioration and degeneration of the musculoskeletal system.
  • the present inventors effectively break this vicious circle and while seeking an effective method to generate a virtuous cycle, the process of the vicious cycle of musculoskeletal function deterioration, from the cause-providing stage (increased cellular stress), to the biochemical risk amplification stage (excessive immune activity) increase) and physiological risk (decreased peripheral blood flow) and physical function decline (muscle reduction, bone density decrease, neurotransmitter function decreased) were classified into 4 stages, and effective reversal of each stage was performed for the reduced musculoskeletal system. It was identified as an essential element to restore function.
  • composition containing phlorotannins having various structures and activities as an active ingredient can achieve this purpose while searching for a component having this effect among natural ingredients that are harmless to the human body. That is, it was confirmed that the composition containing phlorotannin as an active ingredient can improve the overall function of the musculoskeletal system, that is, the motor function, and completed the present invention. In particular, it was confirmed that the composition containing phlorotannin as an active ingredient can solve senile sarcopenia and completed the present invention.
  • the composition of the present invention is a phlorotannin composition optimized for cellular stress reduction activity, immune balance tuning activity, blood circulation promoting activity and neurotransmission promoting activity, and simultaneously provides the three elements of motor function, musculoskeletal tissue, flexibility, and balance, without side effects. can be improved within.
  • the composition of the present invention can improve the function of the musculoskeletal system by improving at least one of muscle mass and bone density, particularly both muscle mass and bone density, and, as a result, can improve exercise function.
  • the composition of the present invention can improve the motor function of the elderly by simultaneously improving the muscle mass and bone density of the elderly over 60 years of age.
  • composition of the present invention can exhibit further effects by ingesting the composition in the form of an aqueous solution under specific conditions (concentration, intake amount, time of intake).
  • Phlorotannin included in the composition for improving motor function by restoring musculoskeletal function of the present invention can be obtained by any conventional method, can also be synthesized using commercially available reagents, and can be obtained by extraction and separation from natural products, particularly seaweed. may be
  • Phlorotannin an active ingredient of the composition of the present invention, can be extracted from brown algae, specifically rhubarb (Eisenia bicyclis), Eisenia arborea (Eisenia arborea), Eisenia desmarestioides (Eisenia desmarestioides), children Eisenia galapagensis, Eisenia masonii, Ecklonia kurome, Ecklonia cava, Ecklonia stolonifera, sea bamboo (Ecklonia maxima), Ecklonia radiata (Ecklonia radiata), Ecklonia bicyclis, Ecklonia biruncinate, Ecklonia buccinalis, Ecklonia caepaestipes, Ecklonia exas Ecklonia exasperta, Ecklonia fastigiata, Ecklonia brevipes, Ecklonia arborea, Ecklonia latifolia, Ecklonia murati Ecklonia muratii), Ecklonia radicosa, Ecklonia richardiana, and Ecklonia wrightii may be
  • the phlorotannin compound is preferably an Ekcol-based compound represented by the following Chemical Formula 1-12 among phlorotannin compounds.
  • Ekkol-based compounds have a relatively small molecular weight, and have a three or five fused ring system, with a hard and flat planar structure, and di-hydroxyphenyl or tri-hydroxyphenol ( Because it can have various conformations through free rotation of tri-hydroxyphenyl) groups, various physiological activities can be exhibited according to the specific structure of each compound in various tissues of the human body.
  • the phlorotannin compound which is an active ingredient of the composition of the present invention, may more preferably be at least one compound selected from compounds of the following Chemical Formulas 1 to 12.
  • the composition for improving exercise function of the present invention may contain 0.001-100% by weight of the phlorotannin compound, preferably 0.1-100% by weight.
  • the composition for improving exercise function of the present invention may contain 0-99.999% by weight of water.
  • the composition of the present invention contains at least one phlorotannin selected from Chemical Formula 7, which is excellent in cell stress reducing activity, and Chemical Formula 1 to 6, which has excellent immune balance promoting activity and blood circulation promoting activity, and Chemical Formula 8 to excellent neurotransmission promoting activity.
  • Chemical Formula 7 which is excellent in cell stress reducing activity
  • Chemical Formula 1 to 6 which has excellent immune balance promoting activity and blood circulation promoting activity
  • Chemical Formula 8 to excellent neurotransmission promoting activity.
  • the composition for improving motor function of the present invention is preferably at least one phlorotannin selected from phlorotannins of Chemical Formula 7 and Chemical Formulas 1 to 6, and at least one phlorotannin selected from Chemical Formulas 8 to 12 phlorotannin.
  • rotannin is contained in 5-50%, 15-65%, and 10-50% by weight, respectively, cellular stress reduction activity, immune balance promoting activity, blood circulation promoting activity, and neurotransmission promoting activity necessary for recovery of musculoskeletal function are simultaneously and synergistic. As a result, it can exert its effect in a negative way, resulting in the improvement of motor function.
  • the composition for improving exercise function of the present invention comprises 15 to 40% by weight of phlorotannin of Formula 2, 5 to 50% by weight of phlorotannin of Formula 7, and 10 to 50% by weight of phlorotannin of Formula 10 with respect to the total weight
  • the composition for improving exercise function of the present invention is 1 to 35% by weight of phlorotannin of Formula 1, 1 to 50% by weight of phlorotannin of Formula 2, 1 to 50% by weight of phlorotannin of Formula 3, with respect to the total weight of the composition for improving exercise function of the present invention Phlorotannin of 0.5 to 10% by weight of 4, phlorotannin of 0.5 to 10% by weight of Formula 5, phlorotannin of 0.5 to 10% by weight of Formula 6, phlorotannin of 15 to 65% by weight of Formula 7, Formula 8 Phlorotannin 0.1 to 20% by weight, phlorotannin 0.1 to 20% by weight of Formula 9, phlorotannin 1 to 30% by weight of Formula 10, phlorotannin 1 to 20% by weight of Formula 11, and fluoro of Formula 12 If 0.1 to 20% by weight of tannins are included, it may bring about an effect of improving exercise function.
  • the composition of the present invention When the composition of the present invention is ingested as an aqueous solution, the effect may be excellent.
  • the composition of the present invention contains phlorotannin at a concentration of 0.1 to 100 ppm, preferably 10 to 200 mL, preferably 50 to 200 mL, in an aqueous solution of 1-100 ppm at a concentration of 20 to 50 ° C.
  • the esophagus, small intestine, Absorption in the entire gastrointestinal tract, including the large intestine is accelerated, improving the musculoskeletal system and improving motor function.
  • composition for improving exercise function of the present invention can be consumed on an empty stomach or with food and beverages and after a meal, but it is more effective when taken on an empty stomach, particularly right after waking up in the morning, or during a rest period of the human body, such as just before going to bed in the evening.
  • the present invention provides a product for enhancing or improving exercise function comprising the composition for improving exercise function.
  • the product for improving exercise function containing the phlorotannin may be commercialized in the form of a liquid, powder, effervescent tablet, protein bar, capsule, etc., but is not limited thereto.
  • the product for improving exercise function containing phlorotannin of the present invention is provided in a liquid form and ingested, or in the form of a powder or effervescent tablet dissolved in water, absorption in the gastrointestinal tract is promoted and musculoskeletal function is provided. can improve motor function as a result.
  • the product for improving exercise function containing phlorotannin of the present invention is provided in the form of a protein bar or capsule, it is preferable to consume it with sufficient water to promote absorption.
  • the product of the present invention contains phlorotannin at a concentration of 0.1 to 100 ppm, preferably at a concentration of 1-100 ppm, in an aqueous solution at 20-50 ° C. 10 to 200 mL, preferably 50 to 200 mL, when ingested at a time, esophagus, small intestine, large intestine Absorption in the entire gastrointestinal tract is promoted, thereby improving the musculoskeletal system function, thereby improving motor function.
  • the product of the present invention contains at least one selected from the group consisting of protein, glycosidal saponin, inositol, glucomanan, dextrin, amino acids, inorganic salts and vitamins as an auxiliary component together with a composition for improving exercise function containing phlorotannin. If it is further included, it is possible to improve the musculoskeletal system function.
  • the daily usage of phlorotannin contained in the composition and product for improving exercise function of the present invention is preferably about 0.1 to 100 mg based on a 50 kg adult, but the usage is not limited to the above range.
  • the product for improving motor function of the present invention can improve muscle mass, bone density, flexibility and sense of balance when ingested in a liquid form containing 1 to 100 ppm of phlorotannin compound, 10 to 2000 mL, preferably 50 to 500 mL per day. there is.
  • composition containing phlorotannin as an active ingredient of the present invention was extracted from Ecklonia cava , a brown algae collected near Jeju Island, by the following method.
  • Ecklonia cava was washed with distilled water to remove foreign substances, dried in the shade, and crushed. Put 5 kg of Ecklonia cava in an extraction container, and 20 times the weight of Ecklonia cava, 30% by weight aqueous solution of alcohol was added, and extracted under reflux at 75 to 80° C. for 4 hours to obtain an extract. The extract was filtered through a 10 ⁇ m filter, and the filtered extract was concentrated under reduced pressure in a water bath at 55° C. to obtain a primary extract concentrate. The primary extract concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 1700 g of the primary extract.
  • the primary extract was dissolved in hot water at 50° C., adsorbed on an adsorption resin, washed with water, and eluted with alcohol to obtain a phlorotannin eluate.
  • the eluate was filtered through a 1 ⁇ m filter, and the filtered extract was concentrated under reduced pressure in a water bath at 55° C. to obtain a secondary extract concentrate.
  • the secondary extract concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 300 g of the secondary extract.
  • the secondary extract was dissolved in alcohol, and filter aid (diatomaceous earth or bentonite) was added and filtered to obtain an eluate.
  • the eluate was filtered through a 1 ⁇ m filter, and the filtered eluate was concentrated under reduced pressure in a water bath at 55°C to obtain a concentrate.
  • the concentrate was dried in a vacuum dryer at 90° C. for at least 8 hours at a pressure of 70 torr, and then pulverized to obtain 190 g of a tertiary extract.
  • the tertiary extract obtained above was loaded on liquid chromatography to proceed with compound separation to obtain 104 g, 18 g and 33 g of phlorotannin fractions I, II and III, respectively.
  • each of the three fractions obtained was dissolved in 60% methanol, filtered with 0.2 ⁇ m membrane filter paper, and loaded into high performance liquid chromatography.
  • the column was HP ODS Hypersil, the solvent was distilled water and methanol, and the solvent was supplied at a flow rate of 1.0 ml/min. From 15% to 70% of methanol, a linear gradient was performed over 30 minutes. Then, compounds of Formulas 1 to 12 were obtained, which were identified by NMR or the like.
  • the dry weight of the separated compound is shown in Table 1 below.
  • Formula 1 Formula 2 Formula 3
  • Formula 4 Formula 5
  • Formula 6 Formula 7
  • Formula 8 Formula 9
  • Formula 10 Formula 11
  • Weight 20.0 26.1 17.9 14.8 9.0 8.4 13.9
  • ER Stress-reducing activity The effect on ER Stress, which refers to stress at the cellular level, was measured.
  • 1000 nM of Thapsigargin which is well known to cause apoptosis by ER stress, was added and treated for 24 hours, followed by MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution treatment (2h, 37°C, 5% CO2) and formazan production was measured at 540nm to measure the degree of apoptosis relief for each compound.
  • Immune balancing activity Aging is accompanied by chronic inflammation and disrupts the immune balance.
  • Biochemically since NFkB, an inflammation-inducing transcription factor, is chronically activated and induces degeneration of musculoskeletal tissue, the degree of activation of NFkB was measured.
  • RAW 264.7 macrophage cell line was transfected with NFkB-Luc reporter plasmid (Clontech, Shiga, Japan), treated with 10 ⁇ M of each compound of Formula 1-12 for 1 hour, and then treated with LPS (1 ⁇ g/mL) for 24 hours. NFkB activation was measured by measuring luciferase activity.
  • Blood circulation promoting activity Aging causes the tendency of blood to overcoagulate and physiologically decreases blood circulation, thereby reducing homeostasis of musculoskeletal tissue and contributing to degeneration. Therefore, aPTT, a representative index of blood coagulation rate, was measured. After mixing 10 ⁇ L of each of the compounds of Formulas 1 to 12 at a concentration of 100 ⁇ M in citric acid-treated normal human plasma (90 ⁇ L), the mixture was left at 37° C. for 1 minute. Then, after adding 100 ⁇ L of aPTT assay reagent (Fisher Diagnostics, USA), it was left at 37° C. for 1 minute, and then 20 mM CaCl 2 (100 ⁇ L) was added to measure the time (seconds) required for coagulation.
  • aPTT assay reagent (Fisher Diagnostics, USA)
  • Acetylcholine a neurotransmitter, is required to trigger the movement of musculoskeletal tissue, and acetylcholine is insufficient in the nerves of aging tissues. Therefore, the inhibitory activity on acetylcholine hydrolase (AChE) that degrades acetylcholine was measured.
  • AChE acetylcholine hydrolase
  • DTNB 5,5'-dithiobis(2-nitrobenzoic acid) solution (900 ⁇ L of 5.55mM DTNB in 50mM potassium phosphate buffer, pH 7.4), ATCh (Acetylthiocholine chloride) solution (2mM ATCh, 25 ⁇ L) and 1mM concentration of Formula 1 ⁇
  • ATCh Alcoholthiocholine chloride
  • compositions and dextrin were mixed in a weight ratio of 1:99 to prepare Product Examples 1 to 9 each containing 1% of the compositions 1 to 9. Since all the compositions had no particular taste, but had a pale yellow color, a small amount of caramel pigment was added to the dextrin to prepare a placebo product (Comparative Product Example 1) in which walking and taste were indistinguishable from the composition.
  • T-score bone density
  • %FFMI muscle mass
  • Lower extremity flexibility (left flexion: Sit & Reach Flexibility Test) was measured as follows. Sitting on a 40 cm high measuring table with both feet spread 5 cm apart, the Trunk Flexion Tester was pushed to the maximum. Shaking the upper body, the body was not bent forward by the recoil, and the knee was kept straight during measurement. Also, the tip of one hand was placed on the same line as the tip of the other, and when the upper body was bent forward, the head was placed between the arms. The unit was set to 0.1 cm, and the best record was selected as a result of three measurements.
  • the one-legged test can quantitatively measure postural balance and is a convenient method (Rossiter-Fornoff, Wolf, Wolfson, Buchner & FICSIT Group, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 50 ( 6), M291 -M297 (1995), in this study, the leg was lifted backward, the knee joint was bent at 90 degrees, both eyes were open, and the time until the foot of the raised leg touched the ground was measured. A total of two measurements were taken and the highest record was used.
  • Preparation and intake method of test drink Every evening, put Product Examples 1 to 9 or Comparative Product Example 1 into a 500 mL thermos in the same amount as one plastic spoon (700 mg capacity) provided in advance, and put it at 40-50 ° C. 500mL of mineral water was added, the lid was closed, and completely dissolved by shaking. Immediately after waking up the next day, 150 mL was taken on an empty stomach, a total of 200 mL was freely ingested between meals, and the remaining 150 mL was taken on an empty stomach before bedtime. The temperature of the solution at the time of ingestion was in the range of 25-40 °C. The results are shown in Table 4 below.
  • composition 8 was administered in 3 concentrations of aqueous solution (1ppm, 20ppm and 100ppm, 200mL ingestion at a time, aqueous solution temperature 15 ⁇ 25°C) and capsules (90mg per capsule, 1time) 2 capsules were taken in the form of 200mL of room temperature water (15 ⁇ 25°C) every day for 7 days immediately after waking up and right before going to bed, and the improvement of trunk muscle function compared to before intake was evaluated.
  • Humac NORM CSMi Co., USA
  • Humac NORM CSMi Co., USA
  • Humac NORM CSMi Co., USA
  • Warm-up exercises were performed freely for ⁇ 10 minutes.
  • the chest, pelvic, and knee were firmly fixed using a strap, a belt, and a fixed pad.
  • Gravity reduction was performed so that gravity caused by the body mass was not reflected during measurement, and the range of motion (ROM) during measurement was extended from -10° ⁇ to flexion 60°.
  • Trunk flexion and extension strength were measured 4 times at 30°/sec, 4 times at 60°/sec, and 4 times at 90°/sec, and peak torque (Nm) was measured per body weight (%BW). did.
  • Adaptation exercises were performed 4 times for each angular velocity, and the rest time between measurements was set to 20 seconds.
  • Daily intake of composition 9 0.4 mg 8 mg 40mg 360mg Trunk flexion maximum force @30 degrees/sec 19.7 25.3 27.4 15.3 Trunk extension maximum force @30 degrees/sec 18.8 23.1 24.9 14.2 Trunk flexion maximum force @60 degrees/sec 19.1 24.7 22.2 13.4 Trunk extension maximum force @60 degrees/sec 10.8 17.4 21.3 9.2 Trunk Bend Maximum Couple @90 degrees/sec 22.6 27.9 29.0 15.3 Trunk extension max. force @90 degrees/sec 21.5 29.3 31.3 16.4 total improvement 112.5 147.7 156.1 83.8
  • Total daily intake (mg) 10.0 10.0 10.0 10.0 10.0 10.0 10.0 Concentration of composition in aqueous solution (ppm) 100 50 33.3 25 Capsules with 5mg Serving amount (mL) of aqueous composition 50 100 150 200 Take with 150mL of water Improvement rate of left abduction compared to before intake (%) 12.8 22.7 27.5 20.8 2.3
  • product example 7 drinks (25ppm concentration, total 300mL) were administered in two ways for one week each - (1) Two times in the daytime (1 time between breakfast and lunch) , between lunch and dinner) and (2) immediately after waking up in the morning + before going to bed in the evening - twice a time, 150mL each, and the degree of improvement in motor function compared with before intake was evaluated. The results are shown in Table 7. As a result, the method (2) showed a superior improvement effect. Therefore, it was found that the injection of the composition into the gastrointestinal tract during the resting period of the human body is more effective than the input during the active period.
  • composition of the present invention can be used to improve exercise function by comprehensively improving the functions of the musculoskeletal system through oral intake, and in particular, when the product of the present invention is ingested, bone density, muscle mass, flexibility and sense of balance are overall improved, It can improve the quality of sports and artistic activities.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à une composition ayant l'effet d'améliorer la fonction athlétique en améliorant de manière complète la fonction du système musculo-squelettique par ingestion par voie buccale. Plus spécifiquement, la présente invention se rapporte à une composition comprenant un composé phlorotannine comme ingrédient actif, et des produits associés, qui peuvent être ingérés sous une forme de boisson pour améliorer de manière complète la densité osseuse, la masse osseuse, la flexibilité, et l'équilibrioception, et ainsi peut être utilisée pour contribuer à accroître la qualité de vie, les activités sportives, et artistiques qui nécessitent sensiblement le fonctionnement réussi du système musculo-squelettique.
PCT/KR2021/000645 2020-01-17 2021-01-18 Composition d'amélioration de la fonction athlétique, comprenant de la phlorotannine comme ingrédient actif WO2021145742A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2020-0006556 2020-01-17
KR1020200006556A KR20210093408A (ko) 2020-01-17 2020-01-17 플로로탄닌을 유효성분으로 포함하는 근골격계 기능 개선용 조성물
KR10-2021-0005925 2021-01-15
KR1020210005925A KR102594284B1 (ko) 2021-01-15 2021-01-15 플로로탄닌을 유효성분으로 포함하는 운동 기능 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2021145742A1 true WO2021145742A1 (fr) 2021-07-22

Family

ID=76863883

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/000645 WO2021145742A1 (fr) 2020-01-17 2021-01-18 Composition d'amélioration de la fonction athlétique, comprenant de la phlorotannine comme ingrédient actif

Country Status (1)

Country Link
WO (1) WO2021145742A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080005711A (ko) * 2006-07-10 2008-01-15 부경대학교 산학협력단 플로로탄닌을 함유한 메트릭스 메탈로프로테이나제 활성억제용 조성물
KR20150135136A (ko) * 2014-05-23 2015-12-02 주식회사 비비에이치씨 플로로탄닌 분획물을 이용한 중간엽 줄기세포로부터 유도만능 줄기세포를 제조하는 방법
KR20170050392A (ko) * 2015-10-30 2017-05-11 주식회사 보타메디 플로로탄닌, 홍삼 추출물 및 카페인을 포함하는 음료 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080005711A (ko) * 2006-07-10 2008-01-15 부경대학교 산학협력단 플로로탄닌을 함유한 메트릭스 메탈로프로테이나제 활성억제용 조성물
KR20150135136A (ko) * 2014-05-23 2015-12-02 주식회사 비비에이치씨 플로로탄닌 분획물을 이용한 중간엽 줄기세포로부터 유도만능 줄기세포를 제조하는 방법
KR20170050392A (ko) * 2015-10-30 2017-05-11 주식회사 보타메디 플로로탄닌, 홍삼 추출물 및 카페인을 포함하는 음료 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARADENIZ FATIH; AHN BYUL-NIM; KIM JUNG-AE; SEO YOUNGWAN; JANG MI-SOON; NAM KI-HO; KIM MIHYANG; LEE SANG-HYEON; KONG CHANG-SUK: "Phlorotannins suppress adipogenesis in pre-adipocytes while enhancing osteoblastogenesis in pre-osteoblasts", ARCHIVES OF PHARMACAL RESEARCH, NATL. FISHERIES UNIVERSITY , PUSAN, KR, vol. 38, no. 12, 23 July 2015 (2015-07-23), KR, pages 2172 - 2182, XP035958489, ISSN: 0253-6269, DOI: 10.1007/s12272-015-0637-0 *
OH JUNG HWAN, AHN BYUL-NIM, KARADENIZ FATIH, KIM JUNG-AE, LEE JUNG IM, SEO YOUNGWAN, KONG CHANG-SUK: "Phlorofucofuroeckol A from Edible Brown Alga Ecklonia Cava Enhances Osteoblastogenesis in Bone Marrow-Derived Human Mesenchymal Stem Cells", MARINE DRUGS, vol. 17, no. 10, 21 September 2019 (2019-09-21), pages 543, XP055828522, DOI: 10.3390/md17100543 *

Similar Documents

Publication Publication Date Title
CN1119154C (zh) 双歧三联活菌制剂及制备方法
CN113398144B (zh) 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用
Olsen Lesions of peripheral nerves developing during coma
WO2021145742A1 (fr) Composition d'amélioration de la fonction athlétique, comprenant de la phlorotannine comme ingrédient actif
Strauss THE THERAPEUTIC USE OF VITAMIN B, IN POLYNEURITIS AND CARDIOVASCULAR CONDITIONS: CLINICAL INDICATIONS
KR101859166B1 (ko) 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물
KR101689259B1 (ko) 데커신 및/또는 데커시놀 안젤레이트 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물, 쌀눈 추출물, 무말랭이 추출물을 유효성분으로 포함하는 운동에 기한 피로 또는 스트레스의 예방 또는 회복용 조성물
KR102594284B1 (ko) 플로로탄닌을 유효성분으로 포함하는 운동 기능 개선용 조성물
KR101046787B1 (ko) 숙취해소용 음료수 조성물
WO2004047766A2 (fr) Traitement d'une amyotrophie spinale
KR101870280B1 (ko) 육계 및 육계나무의 엽병을 유효성분으로 함유하는 숙취 해소용 조성물
JPH05271063A (ja) 活性酸素消去・除去剤
CN106177227A (zh) 一种增强人体免疫力的含辅酶q10的组合物
KR20210093408A (ko) 플로로탄닌을 유효성분으로 포함하는 근골격계 기능 개선용 조성물
Corsello et al. Nutraceuticals and biotics in pediatric gastrointestinal disorders
WO2012096475A2 (fr) Composition pour aliment fonctionnel dont l'effet est de rétablir la composition et la fonction du sang
CN101143203A (zh) 一种具有护肝养胃功能的复方口服液
CN102362936A (zh) 鸡爪芋提取物的用途及其药品和保健品固体制剂、饮料制剂
CN110720527A (zh) 一种中药减肥茶
CN109601996A (zh) 一种具有辅助降血脂作用的组合物及其应用
CN114712424B (zh) 一种具有解酒保肝作用的中药制剂及其制备方法和应用
CN1537603A (zh) 一种脐膏贴及其制备方法
Hutchison The elements of medical treatment
CN100366721C (zh) 以芦荟为主要中药原料的低度酒及其制造方法和应用
KR20160009345A (ko) 데커신 및/또는 데커시놀 안젤레이트 또는 데커신 및/또는 데커시놀 안젤레이트를 유효성분으로 하는 당귀추출물, 쌀눈 추출물, 무말랭이 추출물을 유효성분으로 포함하는 알코올성 숙취 예방, 숙취 해소, 간장 보호 또는 피로 회복용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21741179

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21741179

Country of ref document: EP

Kind code of ref document: A1